摘要
目前 ,^(1 31)I治疗甲状腺疾病的研究有两个主要趋向。首先 ,治疗甲状腺疾病的应用范围有所扩大 ,过去我们仅用 1 31 I治疗 Graves’病、Plumm er氏病或毒性结节性甲状腺肿伴甲亢以及甲状腺癌 ,而现在还用于一些甲状腺功能正常的甲状腺疾病 ,例如非毒性多结节甲状腺肿、单纯弥漫性甲状腺肿 ,甚至甲状腺囊肿。由于 1 31 I治疗较其他方法安全、简便 ,价格便宜 ,因而扩大其应用范围是十分合理的 ;第二 ,1 31 I与其他药物联合应用以减少甲低的发生以及提高其治疗效果 ,称之为综合性治疗 ,其所用药物有抗甲状腺药物、肾上腺能 β受体阻滞剂、甲状腺激素。
At present time, there are two current trends of research on 131 I therapy for thyroid diseases. The first is extension of the application on the field of thyroid diseases. Formerly, we use the 131 I only on the hyperthyroidism of Graves'disease,plummer's disease or toxic nodular goiter as well as thyroid cancer, but now, also for some thyroid diseases with normal thyroid function, such as nontoxic multinodular goiter, simple diffuse goiter even the thyroid cyst. It seems quite rational to use the 131 I more widely, because it is really safe, easy and cheaper than others. The second trend is using 131 I combined together with other drugs in order to reduce the occurrence of hypothyroidism and enhance the therapeutic effect. Authors call it as combined therapy. Drugs recommended for such therpy are antithyroid drugs, β adrenergic receptor blocking agents, thyroid hormone, gtucocorticoid as well as Chinese herb drugs and so on.
出处
《国外医学（放射医学核医学分册）》
2000年第3期97-100,共4页
Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
